BioVeris Completes Agreement With TheraCarb, Inc.
Secures Option for Exclusive Rights to Vaccine Candidate for Candida
20-Jan-2006 -
BioVeris Corporation announced that it has entered into an option agreement with TheraCarb, Inc. for exclusive patent rights to a vaccine candidate for Candida albicans, the most common fungal pathogen affecting humans. Under the agreement with TheraCarb, the Company acquired a first option for ...
candida
clinical trials
regulatory approval